Santos da Silva Jorge 4
4 · MoonLake Immunotherapeutics · Filed Feb 20, 2024
Insider Transaction Report
Form 4
Santos da Silva Jorge
DirectorChief Executive Officer
Transactions
- Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-15$60.18/sh−20,000$1,203,600→ 3,147,554 total - Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-16$60.15/sh−20,000$1,203,000→ 3,127,554 total - Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-20$57.44/sh−20,000$1,148,800→ 3,107,554 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.185 to $63.95. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.335 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F4]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.115 to $59.21. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.